NanoGroup S.A. announced the acquisition of 162,500 shares of the technology company Medinice S.A. at a price of PLN 8 per share, which in total constitutes an investment worth PLN 1.3 million. The transaction was announced on October 16, 2024 and was executed on the Warsaw Stock Exchange as part of a block transaction, outside the quotation system.
At the same time, NanoGroup has entered into an agreement with eCapital, which assumes the possibility of reselling the acquired shares at a price not lower than the purchase price. The agreement gives NanoGroup complete security of the transaction, causing it to have no financial risk related to the possibility of losing financial resources, while allowing it to consume the potential successes of Medinice. The agreement was concluded on October 16 this year and is valid for a year.
Medinice S.A. is a Polish company founded in 2012, specializing in the creation and commercialization of innovative, minimally invasive medical solutions, especially in the fields of cardiology and cardiac surgery. The company’s portfolio currently includes several projects with global potential, at various stages of development. Medinice is approaching the certification of the first projects and potential partnering transactions.
The unique nature of the transaction
It is worth emphasizing that this transaction is of an exceptional nature and constitutes a purely financial action, which was possible only thanks to the appropriate security of the investor. NanoGroup does not plan to carry out similar actions in the future, as the company focuses on its core business, i.e. research and development works and the implementation of key projects, such as the NanOX system.
NanoGroup remains focused on its innovative biotechnology and nanotechnology businesses and the Medinice transaction is a one-time, risk-free transaction that does not distract from the company’s core projects.